Ofev
Developed to target idiopathic pulmonary fibrosis to alleviate breathing difficulties.
Strengths: 100mg
Where to Check Availability
Medicine details
- Therapeutic class
Antifibrotic agent
- Pharmacological class
Tyrosine kinase inhibitor
- Contraindications
hypersensitivity to nintedanib; severe hepatic impairment; pregnancy
- Minor side effects
nausea; diarrhoea; abdominal pain; vomiting; decreased appetite
- Moderate side effects
elevated liver enzymes; hypertension; weight loss
- Dosage forms
Capsule, soft
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Boehringer Ingelheim
- Onset Time
1–2 weeks
- Duration
Ongoing
- Storage instructions
Store below 25°C in the original blister pack.
- Drug interactions
P-glycoprotein inhibitors; CYP3A4 inhibitors
- Age restrictions
Not recommended for children and adolescents under 18 years.
Precautions and warnings
monitor liver function regularly; maintain adequate hydration; avoid cigarette smoking during treatment; use caution with anticoagulant therapy
Serious side effects
haemorrhage — requires immediate medical attention; arterial thromboembolism — requires immediate medical attention; gastrointestinal perforation — requires immediate medical attention
Patient summary
Developed to target idiopathic pulmonary fibrosis to alleviate breathing difficulties.
Mechanism of action
Nintedanib acts as a multiple tyrosine kinase inhibitor. It inhibits pathways involved in fibrosis, preventing the development of scar tissue in the lungs and slowing the decline of lung function.
Pregnancy and breastfeeding
Pregnancy: Use is contraindicated during pregnancy. Breastfeeding: Breastfeeding must be discontinued during treatment.
Ofev
Developed to target idiopathic pulmonary fibrosis to alleviate breathing difficulties.
Editorial Notes
- Active ingredient(s): Nintedanib
- Listed indication(s): Idiopathic Pulmonary Fibrosis, Chronic Fibrosing Interstitial Lung Disease
Available option
- 30 capsules - 100 mg1470-100-mg-17988